On October 8, 2025, ARS Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced the Opposition Division of the European Patent Office (EPO) upheld the validity of all claims in EP 3678649, a patent validated in over 30 European countries related to neffy® (epinephrine nasal spray). ARS Pharma’s issued global intellectual property portfolio related to neffy provides coverage until at least 2039.

The Wilson Sonsini patent team that advised ARS Pharma was led by Val Zunic and included Mike Hostetler and Kaia Parenti.

For more information, please see ARS Pharma’s press release.